What is Spravato?
Spravato is an innovative prescription medication designed to treat depression, specifically for adults with:
- Treatment-resistant depression (TRD)
- Major depressive disorder (MDD) with acute suicidal ideation or behavior
Approved by the FDA in 2019, Spravato is the brand name for esketamine, a nasal spray derived from ketamine. It’s used in conjunction with oral antidepressants to provide rapid relief for those who haven’t responded adequately to at least two other antidepressant treatments.
Advantages of Spravato (Esketamine) Therapy
- Administered as a spray nasally
- NO needles or IV fluids
How Does Spravato Work?
Spravato works differently from traditional antidepressants, offering a unique approach to treating depression:
Administration and Effectiveness
- Spravato is administered as a nasal spray under medical supervision in REMS-certified clinics.
- Patients are monitored for at least two hours after each dose due to potential side effects.
- The treatment involves an initial phase with twice-weekly doses, followed by a maintenance phase with less frequent dosing
- Clinical trials have shown significant reductions in depressive symptoms for people with TRD and MDD experiencing suicidal thoughts, with noticeable improvements within 24 hours.